In a report released on January 7, Gregory Renza from RBC Capital maintained a Hold rating on Verrica Pharmaceuticals (VRCA – Research Report), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback